_×
  0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Recombinant Protein > Human Cell Expressed > Rat IL1RN / IL1RA Protein

Rat IL1RN / IL1RA Protein (Cytokine) PDF Download

Catalog Size (Price) Quantity In Stock Operation Other Information
80073-R01H
  YES          

Protein Production & Purification Service

Interleukin 1 receptor antagonist Protein Datasheet

 

IL1RN / IL1RA Protein Price Inquiry ( Available Sizes )

IL1RN / IL1RA Protein Product Information

Synonym : IL1RN, Il-1ra
Protein Construction:

A DNA sequence encoding the rat IL1RN(P25086)(His27-Gln178) was expressed, fused with Fc region of human IgG1 at the N-terminus.

Source: Rat
Expression Host: Human Cells

IL1RN / IL1RA Protein QC Testing

Purity: > 85 % as determined by SDS-PAGE SDS-PAGE:
SDS-PAGE

IL1RN / IL1RA protein

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
Stability: Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal: Glu
Molecular Mass:

The recombinant rat IL1RN comprises 412 amino acids and predicts a molecular mass of 45.8 kDa. The apparent molecular mass of  the recombinant protein is approximately 47 kDa in SDS-PAGE under reducing conditions due to glycosylation.

Formulation: Lyophilized from sterile PBS, pH7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.

IL1RN / IL1RA Protein Usage Guide

Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

IL1RN / IL1RA Protein Related Products & Topics

Related Areas:

Cancer>>Angiogenesis>>Cytokines/Chemokines in Angiogenesis>>IL-1RA/IL-1F3

Immunology>>Cytokine & Receptor>>Interleukin & Receptor>>IL-1 superfamily and IL-1R/TLR family >>IL-1RA/IL-1F3

Proteins:

Molecule Species Description //For Detailed Info. and Price------CLICK! Cat. No
IL-1RA/IL-1F3 Human IL-1RA/IL-1F3/Fc Protein, Recombinant 10123-H01H
IL-1RA/IL-1F3 Human IL-1RA/IL-1F3 Protein, Recombinant, with Native 10123-HNAE
IL-1RA/IL-1F3 Rat IL1RN / IL1RA Protein, Recombinant 80073-R01H

Antibodies:

Molecule Application Description //For Detailed Info. and Price------CLICK! Cat. No
Huma
IL-1RA/IL-1F3
WB, ELISA IL-1RA/IL-1F3 Antibody, Rabbit MAb 10123-R001
Huma
IL-1RA/IL-1F3
WB, FCM IL-1RA Antibody ( FITC ) 10123-R004-F
Huma
IL-1RA/IL-1F3
WB, ELISA IL-1RA/IL-1F3 Antibody, Mouse MAb 10123-MM12

IL1RN / IL1RA Protein Description

IL1 is an important prototypic pro-inflammatory cytokine that affects multiple cell types, often in concert with another cytokine, tumor necrosis factor (TNF). There are two forms of IL1, IL1α. and IL1β, whose function are mediated by the two specific receptors on the cell surfaces. The IL1 receptor antagonist (IL1RA), formerly called the IL1 inhibitor, is a member of the IL1 cytokine family which binds to the same receptor (IL1R) as IL1, and thus prevents IL1 from signal transduction without interaction with the IL1 molecules. In terms of protein similarities,IL1RA is more closely related to IL1β than it is to IL1α. IL1RA modulates a variety of IL1-related immune and inflammatory responses, and accordingly, the balance between IL1 and IL1Ra in local tissues plays an important role in the susceptibility to and severity of many diseases. IL1RA is suggested to have possible therapeutic applications in treatment of sepsis, rheumatoid arthritis, and chronic myelogenous leukemia. Four alternatively spliced transcript variants encoding distinct isoforms have been identified, and the isoform 1 of IL1RA is secreted from monocytes, macrophages, neutrophils, and other cells.

References

  1. Haskill S. et al., 1991, Proc Natl Acad Sci. 88: 3681-5.
  2. Sehouli J. et al., 2002, Anticancer Res. 22: 3421-4.
  3. Arend WP. e t al., 1998, Annu Rev Immunol. 16: 27-55.
  4. Dinarello CA. et al., 1997, Cytokine Growth Factor Rev. 8: 253-65.